3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
Irinotecan
4
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pembrolizumab
2
cobimetinib
2
Sunitinib
2
Sorafenib
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
repotrectinib
1
pralsetinib
1
osimertinib
1
lutetium Lu 177 dotatate
1
linifanib
1
guadecitabine
1
golotimod
1
genexol-PM
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
L-BLP25
×
Gastrointestinal
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts